Published in Eur J Immunol on January 01, 2008
Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines (2009) 1.83
Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol (2009) 1.73
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A (2011) 1.39
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology (2012) 1.16
Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One (2011) 1.08
New vaccines against influenza virus. Clin Exp Vaccine Res (2013) 1.04
Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS One (2012) 0.97
Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res (2013) 0.97
The prospects and challenges of universal vaccines for influenza. Trends Microbiol (2013) 0.97
Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. PLoS One (2011) 0.94
Virus-like particles as universal influenza vaccines. Expert Rev Vaccines (2012) 0.93
M2e-Based Universal Influenza A Vaccines. Vaccines (Basel) (2015) 0.93
An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J (2010) 0.91
M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLoS One (2013) 0.89
Universal influenza vaccines, a dream to be realized soon. Viruses (2014) 0.89
Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine. Vaccine (2009) 0.87
Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. Vaccine (2010) 0.87
Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Immunology (2010) 0.86
Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines. Nanomedicine (2013) 0.86
Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration. Influenza Other Respir Viruses (2013) 0.82
Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines. Immune Netw (2015) 0.82
Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses. Proc Natl Acad Sci U S A (2012) 0.81
Recombinant influenza vaccines. Acta Naturae (2012) 0.80
Mucosal vaccine delivery: Current state and a pediatric perspective. J Control Release (2016) 0.80
Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung. Nanomedicine (Lond) (2014) 0.78
A Novel Lactococcal Vaccine Expressing a Peptide from the M2 Antigen of H5N2 Highly Pathogenic Avian Influenza A Virus Prolongs Survival of Vaccinated Chickens. Vet Med Int (2013) 0.77
Development of Recombinant Vaccine against A(H1N1) 2009 Influenza Based on Virus-like Nanoparticles Carrying the Extracellular Domain of M2 Protein. Acta Naturae (2010) 0.77
Design of virus-based nanomaterials for medicine, biotechnology, and energy. Chem Soc Rev (2016) 0.77
Fast vaccine design and development based on correlates of protection (COPs). Hum Vaccin Immunother (2014) 0.77
High-level systemic expression of conserved influenza epitope in plants on the surface of rod-shaped chimeric particles. Viruses (2014) 0.76
Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages. PLoS One (2015) 0.76
Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen. Nano Life (2014) 0.76
Early Transcriptome Signatures from Immunized Mouse Dendritic Cells Predict Late Vaccine-Induced T-Cell Responses. PLoS Comput Biol (2016) 0.75
Distinct T helper cell dependence of memory B cell proliferation versus plasma cell differentiation. Immunology (2016) 0.75
Recombinant adenoviruses displaying matrix 2 ectodomain epitopes (M2e) on their fiber proteins as universal influenza vaccines. J Virol (2017) 0.75
Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate. Antiviral Res (2017) 0.75
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol (2005) 3.14
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol (2005) 2.80
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (2008) 2.77
Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science (2007) 2.67
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol (2004) 2.59
Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 2.54
Brain anatomy and sensorimotor gating in Asperger's syndrome. Brain (2002) 2.26
Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol (2005) 2.19
The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol (2004) 2.11
A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One (2008) 2.07
GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med (2008) 1.99
TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol (2007) 1.95
Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol (2007) 1.92
The coming of age of virus-like particle vaccines. Biol Chem (2008) 1.85
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol (2006) 1.84
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol (2005) 1.84
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol (2004) 1.74
Recall proliferation potential of memory CD8+ T cells and antiviral protection. J Immunol (2005) 1.73
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens (2007) 1.68
Notch-induced T cell development requires phosphoinositide-dependent kinase 1. EMBO J (2007) 1.67
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity (2005) 1.63
Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem (2007) 1.59
Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol (2006) 1.59
CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci U S A (2009) 1.56
Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur J Immunol (2006) 1.52
Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res (2010) 1.52
VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest (2006) 1.51
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 1.48
Slit2 involvement in glioma cell migration is mediated by Robo1 receptor. J Neurooncol (2007) 1.41
Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol (2002) 1.39
A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia (2004) 1.38
Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol (2011) 1.37
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity (2008) 1.34
Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A (2011) 1.33
Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol (2010) 1.32
In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry (2006) 1.29
Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation (2003) 1.29
Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol (2003) 1.26
The COMT val158met polymorphism and brain morphometry in healthy young adults. Neurosci Lett (2006) 1.25
Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells. J Immunol (2004) 1.21
Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A (2005) 1.21
Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A (2008) 1.14
A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol (2007) 1.13
Rapid response of marginal zone B cells to viral particles. J Immunol (2004) 1.13
Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol (2007) 1.12
Versatile virus-like particle carrier for epitope based vaccines. PLoS One (2010) 1.12
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol (2006) 1.11
Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol (2010) 1.11
Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs (2007) 1.11
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol (2002) 1.10
Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol (2012) 1.09
Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol (2003) 1.09
Asperger syndrome: a proton magnetic resonance spectroscopy study of brain. Arch Gen Psychiatry (2002) 1.09
Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol (2012) 1.09
A functional magnetic resonance imaging study of inhibitory control in obsessive-compulsive disorder. Psychiatry Res (2009) 1.08
Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol (2002) 1.07
Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol (2008) 1.07
Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. Am J Psychiatry (2006) 1.06
The effect of pre-mutation of X chromosome CGG trinucleotide repeats on brain anatomy. Brain (2004) 1.06
Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 1.06
Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol (2009) 1.05
Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine (2010) 1.05
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother (2010) 1.04
Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med (2005) 1.04
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci (2011) 1.03
Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med (2007) 1.03
Integrin regulation by RhoA in thymocytes. J Immunol (2005) 1.03
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J (2010) 1.03
White matter integrity in Asperger syndrome: a preliminary diffusion tensor magnetic resonance imaging study in adults. Autism Res (2010) 1.02
Th cells act via two synergistic pathways to promote antiviral CD8+ T cell responses. J Immunol (2010) 1.01
Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol (2005) 1.01
Vaccination against GIP for the treatment of obesity. PLoS One (2008) 1.01
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
Role of IgM antibodies versus B cells in influenza virus-specific immunity. Eur J Immunol (2002) 1.00
Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines (2008) 0.99
Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol (2009) 0.98